Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.

被引：0
作者：
Yabe, Michitoshi
Kenmotsu, Hirotsugu
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Miyawaki, Taichi
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Takahashi, Toshiaki
机构：
[1] Shizuoka Canc Ctr, Sunto Gun, Japan
[2] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Shizuoka, Japan
[4] Shizuoka Canc Ctr, Div Thorac Oncol, Sunto Gun, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21113
引用
收藏
页数：3
相关论文
共 50 条
  • [41] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [42] A pemetrexed-based genetic study of Chinese Han patients with advanced non-small cell lung cancer (NSCLC).
    Lu, Shun
    Niu, Xiaomin
    Li, Ziming
    Yu, Yongfeng
    Ye, Xiangyun
    Liu, Yun
    Chen, Zhiwei
    Kan, Mengyuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
    Waterhouse, David M.
    Espirito, Janet L.
    Chioda, Marc D.
    Baidoo, Bismark
    Mardekian, Jack
    Robert, Nicholas J.
    Masters, Elizabeth T.
    [J]. DRUGS-REAL WORLD OUTCOMES, 2020, 7 (04) : 261 - 269
  • [44] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [45] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [46] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [47] Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
    David M. Waterhouse
    Janet L. Espirito
    Marc D. Chioda
    Bismark Baidoo
    Jack Mardekian
    Nicholas J. Robert
    Elizabeth T. Masters
    [J]. Drugs - Real World Outcomes, 2020, 7 : 261 - 269
  • [48] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [49] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214
  • [50] Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
    Park, Heae Surng
    Lee, June Koo
    Kim, Dong-Wan
    Kulig, Kimary
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. LUNG CANCER, 2012, 77 (02) : 288 - 292
12345